New cancer drug begins first human tests for Tough-to-Treat tumors
NCT ID NCT06484985
Summary
This is the first study in people to test the safety of an experimental drug called AXT-1003. It is for adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The main goal is to find a safe dose and see how the body processes the drug, while also looking for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
-
Fujian Cancer Hospital
RECRUITINGFuzhou, China
-
Hunan Cancer Hosptial
RECRUITINGChangsha, China
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, China
Conditions
Explore the condition pages connected to this study.